Elan
Executive Summary
Reaches agreement giving Syntex exclusive U.S. rights to Elan's once-daily formulation of naproxen, for which an NDA is pending. Syntex and Elan previously had announced a marketing agreement in March 1993; that agreement was terminated in October. Syntex markets immediate-release naproxen as Naprosyn. The U.S. patent for the drug expired in December